Section of Clinical Nutrition and Nutrigenomics, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Health Center srl, via Sabotino 56, 87100 Cosenza, Italy.
Curr Med Chem. 2020;27(2):216-229. doi: 10.2174/0929867326666190326113607.
Obesity is now recognized as a worldwide health issue and has reached epidemic proportions, affecting both developed and developing countries. The World Obesity Federation stated that "Obesity is a chronic relapsing disease process": as a result, obesity has been recognized internationally as a chronic disease. The primary cause of the metabolic syndrome and increase of the cardiovascular risk have been identified in "sick fat", a condition then defined as adiposopathy. Heart attacks, strokes and renal failures are pathologies that have mid-risk factors such as dyslipidemia, hypertension and diabetes, which in turn are caused by obesity, whose primary risk factor is represented by the diet. The aim of the present review is to consider the importance of body composition, together with chronic inflammation and a new gut microbiota data that may turn out to be crucial elements of some target treatment of human obesity.
In this review, we performed research using PubMed database reviewing the evidence in the literature of evidence information regarding the link between obesity and body composition in the development of metabolic disease via inflammation markers and in particular, the new role exerted by gut microbiota.
Several papers were evaluated searching for differences in fat mass and disease risk. We also identified the same papers dealing with differences in body composition and metabolic syndrome. Our attention focuses also on a new frontier of gut microbiota composition in the body weight decrease and anti-inflammatory effects.
To the saving of lean mass, for the prevention of cardiometabolic diseases, also considering the relationship with obesity, it is necessary to reduce the inflammatory state, acting on the gut-microbiota and on the intestinal permeability. To improve the health of the intestinal flora, we propose a 4P medicine and treatment with probiotics, prebiotics, postbiotics, and polyphenols.
肥胖现已被视为全球性健康问题,且已达到流行程度,影响着发达国家和发展中国家。世界肥胖联合会表示:“肥胖是一种慢性复发性疾病过程”:因此,肥胖已被国际公认为一种慢性病。代谢综合征的主要原因和心血管风险的增加已在“病态脂肪”中被发现,这种情况随后被定义为脂肪病。心脏病发作、中风和肾衰竭是具有中等风险因素(如血脂异常、高血压和糖尿病)的病理,而这些反过来又是由肥胖引起的,肥胖的主要风险因素是饮食。本综述的目的是考虑身体成分的重要性,以及慢性炎症和新的肠道微生物组数据,这些可能成为人类肥胖某些靶向治疗的关键因素。
在本综述中,我们使用 PubMed 数据库进行了研究,回顾了有关肥胖与身体成分在通过炎症标志物发展代谢疾病方面的联系的文献中的证据信息,特别是肠道微生物组的新作用。
评估了多篇论文,以寻找脂肪量差异与疾病风险之间的关系。我们还确定了同一批论文,涉及身体成分和代谢综合征的差异。我们的注意力还集中在肠道微生物组组成在体重减轻和抗炎作用方面的新前沿。
为了保存瘦体重,预防心血管代谢疾病,同时考虑到与肥胖的关系,有必要减轻炎症状态,作用于肠道微生物组和肠道通透性。为了改善肠道菌群的健康,我们提出了 4P 医学和益生菌、益生元、后生元和多酚的治疗方法。